Bruker Co. (NASDAQ:BRKR) Stock Holdings Cut by Nebula Research & Development LLC

Nebula Research & Development LLC decreased its position in Bruker Co. (NASDAQ:BRKR) by 77.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,556 shares of the medical research company’s stock after selling 12,373 shares during the quarter. Nebula Research & Development LLC’s holdings in Bruker were worth $208,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Freshford Capital Management LLC bought a new position in shares of Bruker during the 4th quarter valued at about $10,761,000. Pinebridge Investments L.P. boosted its holdings in Bruker by 42.7% during the fourth quarter. Pinebridge Investments L.P. now owns 33,619 shares of the medical research company’s stock worth $1,971,000 after buying an additional 10,055 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Bruker by 3.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 549,490 shares of the medical research company’s stock worth $32,212,000 after buying an additional 19,844 shares during the last quarter. Eversept Partners LP bought a new position in shares of Bruker in the fourth quarter valued at $13,772,000. Finally, Hsbc Holdings PLC boosted its stake in shares of Bruker by 63.0% during the 4th quarter. Hsbc Holdings PLC now owns 25,574 shares of the medical research company’s stock worth $1,499,000 after acquiring an additional 9,888 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BRKR. Stifel Nicolaus cut their target price on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research report on Friday, February 14th. Wells Fargo & Company decreased their target price on shares of Bruker from $75.00 to $60.00 and set an “overweight” rating for the company in a report on Thursday, April 17th. Citigroup reduced their price target on shares of Bruker from $75.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, April 7th. Guggenheim reiterated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Finally, Barclays reduced their target price on Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.00.

Bruker Stock Down 1.8 %

BRKR stock opened at $39.35 on Friday. The firm has a market cap of $5.96 billion, a PE ratio of 51.78, a PEG ratio of 2.16 and a beta of 1.18. The company has a fifty day simple moving average of $42.26 and a 200 day simple moving average of $52.11. Bruker Co. has a 1 year low of $34.10 and a 1 year high of $79.78. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Sell-side analysts anticipate that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were issued a dividend of $0.05 per share. The ex-dividend date was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.51%. Bruker’s dividend payout ratio (DPR) is presently 26.32%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.